Your browser doesn't support javascript.
loading
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Nooka, A K; Costa, L J; Gasparetto, C J; Richardson, P G; Siegel, D S; Chari, A; Lentzsch, S; Jagannath, S; Mikhael, J.
Affiliation
  • Nooka AK; Department of Hematology and Oncology, Winship Cancer Institute, Emory University, Atlanta, GA. Electronic address: anooka@emory.edu.
  • Costa LJ; University of Alabama Blood and Marrow Transplantation Program, University of Alabama at Birmingham, Birmingham, AL.
  • Gasparetto CJ; Duke University School of Medicine, Durham, NC.
  • Richardson PG; Multiple Myeloma Program, Dana-Farber Cancer Institute, Boston, MA.
  • Siegel DS; Division Chief, Multiple Myeloma, Hackensack Meridian Health, Hackensack, NJ.
  • Chari A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Lentzsch S; Division of Hematology and Oncology, Department of Medicine, Columbia University, New York, NY.
  • Jagannath S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Mikhael J; Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute (TGen), City of Hope Cancer Center, Phoenix, AZ.
Clin Lymphoma Myeloma Leuk ; 22(7): e526-e531, 2022 07.
Article in En | MEDLINE | ID: mdl-35361554
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Guideline Limits: Adult / Humans Language: En Journal: Clin Lymphoma Myeloma Leuk Journal subject: NEOPLASIAS Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Myeloma Type of study: Guideline Limits: Adult / Humans Language: En Journal: Clin Lymphoma Myeloma Leuk Journal subject: NEOPLASIAS Year: 2022 Type: Article